NEW YORK (GenomeWeb News) – RNAi research services company Definiens said today that Cenix BioScience has expanded a license agreement to continue to use Definiens’ data extraction technology in its microscopy assays for high throughput RNAi studies in human and rodent cells.
 
Under the agreement, Cenix will integrate the Definiens Cellenger system into its existing high-throughput and high-content RNAi-based research infrastructure, the company said.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.